1-20 of 88
Loic Ysebaert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Tahla Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Österborg, Tadeusz Robak, Martin Simkovic, Don Stevens, Sergey Voloshin, Vladimir I. Vorobyev, Munchi Yagci, Loic Ysebaert, Qianaya Qi, Andrew Steele, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2021) 138 (Supplement 1): 70.
DOI: https://doi.org/10.1182/blood-2021-148666
Published: 2021
Journal Articles

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Franck Morschhauser, Mark Bishton, Toby A. Eyre, Emmanuel Bachy, Guillaume Cartron, Loïc Ysebaert, Sabela Bobillo, Norma C. Gutierrez, L. Elizabeth Budde, Christopher P. Fox, Andrea Knapp, Manejeh Yaqub, Michael C. Wei, Carol O'Hear, Haocheng Li, Enkhtsetseg Purev, William Townsend
Journal: Blood
Blood (2021) 138 (Supplement 1): 129.
DOI: https://doi.org/10.1182/blood-2021-145694
Published: 2021
Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Anne-Sophie Michallet, Anne Quinquenel, Remi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Mad-Helenie Elsensohn, Therese Aurran, Kamel Laribi, Florence Cymbalista, Vincent Levy, Laurence Simon, Damien Roos-Weil, Veronique Leblond, Marie-Sarah Dilhuydy, Cécile Tomowiak, Caroline Dartigeas, Romain Guieze, Olivier Tournilhac, Emmanuelle Ferrant, Sophie de Guibert, Pierre Feugier, Fatiha Merabet, Stéphane Leprêtre, Philippe Carassou, Julie Gay, Bénédicte Hivert, Luc Mathieu Fornecker, Jehan Dupuis, Lysiane Molina, Bruno Villemagne, Guillaume Cartron, Bernard Drenou, Béatrice Mahé, Omar Benbrahim, Xavier Cahu, Christelle Portois, Loic Ysebaert, Florence Nguyen-Khac, Valérie Rouille, Alain Delmer
Journal: Blood
Blood (2021) 138 (Supplement 1): 641.
DOI: https://doi.org/10.1182/blood-2021-145624
Published: 2021
Journal Articles

Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group

Charles Herbaux, Caroline Bret, Roberta Di Blasi, Emmanuel Bachy, David Beauvais, Elodie Gat, Thomas Gastinne, Florence Broussais, Guillaume Cartron, Alexis Cuffel, Loic Ysebaert, Mikael Roussel, Krimo Bouabdallah, Julien Guy, Arnaud Campidelli, François Van Laethem, Rene-Olivier Casasnovas, Remy Dulery, Franck Morschhauser, Sophie Caillat-Zucman, Roch Houot, Steven Le Gouill
Journal: Blood
Blood (2021) 138 (Supplement 1): 743.
DOI: https://doi.org/10.1182/blood-2021-148626
Published: 2021
Journal Articles

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Romain Guieze, Loic Ysebaert, Damien Roos-Weil, Lysiane Molina, Luc Mathieu Fornecker, Thérèse Aurran, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Alain Saad, Sophie de Guibert, Bernard Drenou, Philippe Quittet, Bénédicte Hivert, Kamel Laribi, Julie Gay, Julien Broséus, Valérie Rouille, David Schwartz, Bruno Pereira, Alain Delmer, Pierre Feugier
Journal: Blood
Blood (2021) 138 (Supplement 1): 3570.
DOI: https://doi.org/10.1182/blood-2021-147467
Published: 2021
Journal Articles

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2 ) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean Marc Schiano De Colella, Hervé Tilly, M. Lia Palomba, Emmanuel Bachy, Christophe Fruchart, Edward Libby, Rene-Olivier Casasnovas, Ian W. Flinn, Corinne Haioun, Herve Maisonneuve, Loic Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Steven Le Gouill, Nicolas Daguindau, Vincent Delwail, Gian-Matteo Pica, Alejandro Martin Garcia-Sancho, Armando Lopez-Guillermo, Jean-Francois Larouche, Kiyoshi Ando, Gomes da Silva Maria, Marc André, Ka Lung Wu, Laurie H. Sehn, Koji Izutsu, Guillaume Cartron, Argyrios Gkasiamis, Russell Crowe, Luc Xerri, Nathan H. Fowler, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 2417.
DOI: https://doi.org/10.1182/blood-2021-148218
Published: 2021
Journal Articles

Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab

Charles Herbaux, Stéphanie Poulain, Damien Roos-Weil, Jacques-Olivier Bay, Yann Guillermin, Francois Lemonnier, Kamel Laribi, Sorin Visanica, Jerome Moreaux, Hugo Gonzalez, Maxime Jullien, Abderrazak El Yamani, Houria Debarri, Sophie Godet, Franck Morschhauser, Olivier Tournilhac, Matthew S. Davids, Loic Ysebaert
Journal: Blood
Blood (2021) 138 (Supplement 1): 1201.
DOI: https://doi.org/10.1182/blood-2021-149228
Published: 2021
Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Charles Herbaux, Christoph Kornauth, Stéphanie Poulain, Stephen J. F. Chong, Mary C. Collins, Rebecca Valentin, Liam Hackett, Olivier Tournilhac, François Lemonnier, Jehan Dupuis, Adrien Daniel, Cecile Tomowiak, Kamel Laribi, Loïc Renaud, Damien Roos-Weil, Cedric Rossi, Eric Van Den Neste, Cecile Leyronnas, Fatiha Merabet, Jean Valère Malfuson, Mourad Tiab, Loïc Ysebaert, Samuel Ng, Franck Morschhauser, Philipp B. Staber, Matthew S. Davids
Journal: Blood
Blood (2021) 137 (25): 3495–3506.
DOI: https://doi.org/10.1182/blood.2020007303
Published: 2021
Includes: Supplemental data
Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Clinical Trials & Observations Brief Report
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Carmen Aanei, Michel Ticchioni, Marie-Sarah Dilhuydy, Fabien Subtil, Valerie Rouille, Beatrice Mahe, Kamel Laribi, Bruno Villemagne, Gilles Salles, Olivier Tournilhac, Alain Delmer, Christelle Portois, Brigitte Pegourie, Veronique Leblond, Cecile Tomowiak, Sophie De Guibert, Frederique Orsini Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc-Matthieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Malgorzata Truchan-Graczyk, Jean-Pierre Vilque, Thérèse Aurran, Florence Cymbalista, Stéphane Lepretre, Vincent Levy, Florence Nguyen-Khac, Pierre Feugier
Journal: Blood
Blood (2021) 137 (8): 1019–1023.
DOI: https://doi.org/10.1182/blood.2020008164
Published: 2021
Includes: Supplemental data
Journal Articles

Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Emmanuel Bachy, MD PhD, Vincent Camus, Catherine Thieblemont, MD PhD, Rene-Olivier Casasnovas, MD, Loic Ysebaert, MD PhD, Gandhi Laurent Damaj, MD PhD, Stephanie Guidez, Gian-Matteo Pica, MD, Won Seog Kim, MD PhD, Soon Thye Lim, MBBS, MRCP, FAMS, Marc André, MD, Alejandro Martin Garcia-Sancho, MD PhD, Maria Jesus Penarrubia Ponce, MD, Philipp B. Staber, MD PhD, Judith Trotman, FRACP, Andreas Hüttmann, MD, Vittorio Stefoni, MD PhD, Alessandro Re, MD, Philippe Gaulard, MD PhD, Marie-Helene Delfau-Larue, MD PhD, Laurence De Leval, MD, Michel Meignan, MD, Ju Li, PhD, Franck Morschhauser, MD PhD, Richard Delarue, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–33.
DOI: https://doi.org/10.1182/blood-2020-134440
Published: 2020
Journal Articles

Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

Olivier Tournilhac, MD PhD, Maya Hacini, MD, Kamal Bouabdallah, MD, Kamel Laribi, MD, Marie Maerevoet, MD, Loic Ysebaert, MD PhD, Stephanie Guidez, Steven Le Gouill, MD PhD, Marc André, MD, Jehan Dupuis, MD, Catherine Thieblemont, MD PhD, Emmanuel Bachy, MD PhD, Nicolas Daguindau, MD, Franck Morschhauser, MD PhD, Sabine Tricot, MD, Pierre Feugier, MD PhD, Anne Banos, MD, Thierry Lamy De La Chapelle, MD PhD, Adrien Chauchet, MD, Emmanuel Gyan, MD PhD, Guillaume Cartron, MD PhD, Hassan Farhat, MD, Vincent Camus, Bernard Drenou, MD PhD, Hacene Zerazhi, MD, David Sibon, MD PhD, Emmanuelle Nicolas-Virelizier, MD, Caroline Delette, MD, Sylvia Snauwaert, MD, Nicole Straetmans, MD, Richard Delarue, MD, Marie Parrens, MD, Céline Bossard, MD, Laurence De Leval, MD, Philippe Gaulard, MD PhD, Gandhi Laurent Damaj, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
DOI: https://doi.org/10.1182/blood-2020-139224
Published: 2020
Journal Articles

Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) and Budget Impact Analysis of Venetoclax Plus Obinutuzumab Sequences for CLL Patients Not Eligible for Full Dose Fludarabine in France

Honghao Fang, Harinala Ravonimbola, Nisha C Hazra, Zhou Zhou, MS, Beenish S. Manzoor, PhD MPH, Vincent Levy, MD PhD, Loic Ysebaert, MD PhD, Nathanael Kabore, Kavita Sail
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–29.
DOI: https://doi.org/10.1182/blood-2020-137034
Published: 2020
Journal Articles

Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Romain Guieze, MD, Loic Ysebaert, MD PhD, Lysiane Molina, MD, Damien Roos-Weil, MDPhD, Anne-Sophie Michallet, MD PhD, Benedicte Hivert, MD, Julie Gay, MD, Alain Saad, MD, Luc Mathieu Fornecker, MD PhD, Julien Broséus, Valérie Rouille, Laëtitia Auvray, Alain Jacques Delmer, MD PhD, Pierre Feugier, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
DOI: https://doi.org/10.1182/blood-2020-136667
Published: 2020
Journal Articles

Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Charles Herbaux, MD MSc, Imelda Raczkiewicz, Kamel Laribi, MD, Loic Ysebaert, MD PhD, Agnes Daudignon, Sabine Tricot, Aurelie Caillault-Venet, Alain Jacques Delmer, MD PhD, Pascale Cornillet-Lefebvre, Cymbalista Florence, Virginie Eclache, Pierre Morel, MD, Gauthier Decool, Morgane Nudel, Romain Guieze, MD, Liam Hackett, BS, Stephen Jun Fei Chong, Mary C Collins, BS, Florence Nguyen-Khac, MD PhD, Fatiha Merabet, MD, Jasmine Chauzeix, Stéphanie Struski, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD, Stéphanie Poulain, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
DOI: https://doi.org/10.1182/blood-2020-139210
Published: 2020
Journal Articles

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Clinical Trials & Observations
Cecilia Carpio, Reda Bouabdallah, Loïc Ysebaert, Juan-Manuel Sancho, Gilles Salles, Raul Cordoba, Antonio Pinto, Mecide Gharibo, Drew Rasco, Carlos Panizo, Jose A. Lopez-Martin, Armando Santoro, Antonio Salar, Silvia Damian, Alejandro Martin, Gregor Verhoef, Eric Van den Neste, Maria Wang, Suzana Couto, Soraya Carrancio, Andrew Weng, Xuehai Wang, Frank Schmitz, Xin Wei, Kristen Hege, Matthew W. B. Trotter, Alberto Risueño, Tonia J. Buchholz, Patrick R. Hagner, Anita K. Gandhi, Michael Pourdehnad, Vincent Ribrag
Journal: Blood
Blood (2020) 135 (13): 996–1007.
DOI: https://doi.org/10.1182/blood.2019002395
Published: 2020
Includes: Supplemental data
Journal Articles

Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Edith Julia, Nathan H Fowler, MD, Emmanuel Bachy, MD PhD, Pierre Feugier, MD PhD, Reda Bouabdallah, Herve Tilly, MD PhD, M. Lia Palomba, MD, Christophe Fruchart, MD, Edward N. Libby, III, MD, Rene-Olivier Casasnovas, MD, Ian W. Flinn, MD PhD, Corinne Haioun, MD PhD, Herve Maisonneuve, MD, Loic Ysebaert, MD PhD, Nancy L. Bartlett, MD, Kamal Bouabdallah, MD, Pauline Brice, Vincent Ribrag, MD, Nicolas Daguindau, MD, Steven Le Gouill, Gian-Matteo Pica, MD, Alejandro Martín, MD PhD, Armando Lopez-Guillermo, Jean-Francois Larouche, MD, Kiyoshi Ando, Gomes da Silva Maria, MD PhD, Marc André, Ka Lung Wu, MD, Laurie H Sehn, MD, Kensei Tobinai, MD PhD, Guillaume Cartron, Richard Delarue, Myron Czuczman, Luc Xerri, MD PhD, Gilles A. Salles, MD PhD, Franck Morschhauser, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1524.
DOI: https://doi.org/10.1182/blood-2019-129024
Published: 2019
Journal Articles

Prospective, Multicentric Phase II Randomized Trial Comparing the Efficacy of Methotrexate or Cyclophosphamide in Large Granular Lymphocytic Leukemia: A French National Study. Report on the Interim Analysis

Thierry Lamy, PhD MD, Cedric Pastoret, MD, Roch Houot, MD PhD, Loic Ysebaert, MD PhD, Mathilde Hunault, MD PhD, Gandhi Damaj, Anne Banos, Olivier Tournilhac, Bachra Choufi, Jean-Pierre Marolleau, MD PhD, Jehan Dupuis, MD, Alain Jacques Delmer, MD PhD, Stephane Lepretre, Emmanuel Gyan, MD PhD, Pierre Feugier, MD PhD, Sophie Rigaudeau, MD, Anne Lazareth, MD, Jean Valère Malfuson, MD, Thierry Fest, Eric Bellissant
Journal: Blood
Blood (2019) 134 (Supplement_1): 1545.
DOI: https://doi.org/10.1182/blood-2019-123439
Published: 2019
Journal Articles

Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients

Loic Ysebaert, MD PhD, Anne-Sophie Michallet, MD PhD, Fontanet Bijou, MD, Aline Clavert, MD, Anne Quinquenel, MD, Anne Calleja, Romain Guieze, MD PhD, Emmanuelle Ferrant, MD, Annie Brion, Kamel Laribi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1741.
DOI: https://doi.org/10.1182/blood-2019-122318
Published: 2019
Journal Articles

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Anne-Sophie Michallet, MD PhD, Marie-Sarah Dilhuydy, MD, Fabien Subtil, Valérie Rouille, Beatrice Mahe, MD, Kamel Laribi, MD, Bruno Villemagne, MD, Gilles A. Salles, MD PhD, Olivier Tournilhac, Alain Jacques Delmer, MD PhD, Christelle Portois, Brigitte Pegourie, MD, Veronique Leblond, MD PhD, Cecile Tomowiak, MD, Sophie de Guibert, MD, Frederique Orsini, Anne Banos, MD, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, MD PhD, Loic Ysebaert, MD PhD, Caroline Dartigeas, MD, Margot Truchan, Jean Pierre Vilque, Thérèse Aurran, MD, Florence Cymbalista, MD PhD, Stephane Lepretre, Vincent Levy, MD PhD, Florence Nguyen-Khac, MD PhD, Magali Le Garff-Tavernier, Carmen Aanaei, Michel Ticchioni, Remi Letestu, Pierre Feugier, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3038.
DOI: https://doi.org/10.1182/blood-2019-126720
Published: 2019
Journal Articles

A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study

Herve Ghesquieres, MD PhD, Cedric Rossi, MD PhD, Fanny Cherblanc, PhD, Sandra Le Guyader, PhD, Fontanet Bijou, MD, Pierre Sujobert, MD PhD, Pascale Fabbro-Peray, MD PhD, Luc Mathieu Fornecker, MD PhD, Adeline Bernier, PhD, Isabelle Baldi, MD PhD, Krimo Bouabdallah, MD, Camille Laurent, MD PhD, Lucie Oberic, MD, Nadine Morineau, MD, Gilles A. Salles, MD PhD, Loic Ysebaert, MD PhD, Alain Monnereau, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4762.
DOI: https://doi.org/10.1182/blood-2019-129204
Published: 2019